Vol.18, No.4, 2021, pp.187-199, doi:10.32604/mcb.2021.017750
OPEN ACCESS
REVIEW
A Review of the Role of ERp57 in Cancerous and Non-Cancerous Cell Physiology and its Potential as a Therapeutic Target
  • Fatemeh Rahbar1, Avid Farhang Fagheh2, Ayda Khosravi2, Siavash Shariatzadeh2,3,*, Reza Akhavan-Sigari4
1 Islamic Azad University, Tehran Medical Branch, Tehran, Iran
2 Tehran University of Medical Sciences, Tehran, Iran
3Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 Department of Neurosurgery, University Medical Center Tuebingen, Tuebingen, Germany
* Corresponding Author: Siavash Shariatzadeh. Email:
Received 03 June 2021; Accepted 16 September 2021; Issue published 27 October 2021
Abstract
The protein ERp57 is a stress-responsive protein, mainly exists in the endoplasmic reticulum (ER), and a small amount in the cell membrane, cytoplasm, nucleus and mitochondria, which is involved in the signal transduction from the cell surface, the regulation process that occurs in the nucleus, and the formation of polymer protein complexes involved in DNA repair. Various degrees of ERp57 dysregulation has been observed in many types of non-communicable diseases especially in cancers. Previous studies showed that the expression of ERp57 could play a key role in occurrence and development of cancers such as breast cancer, gastric cancer, ovarian cancer, etc.; in addition, it has been suggested to play a pivotal role in disease progression of non-cancerous diseases such as neurodegeneration, liver disease, kidney disease, intestinal irritability syndrome and airway hypersensitivity. Thus, abnormal expression of ERp57 could be used as promising biomarker for cancer diagnosis and prognosis based on the previous studies. In this regard, current study was aimed to review the literature, which have been elucidate the role of ERp57 protein expression in both non-cancer and cancer disease. Overall, most studies have shown that inhibiting/knocking out of ERp57 could inhibit the cell proliferation and also induce apoptosis in both human cancerous and non-cancerous cells. Also, it has been suggested that the overexpression of ERp57 could intensify the cancer development. Therefore, it could be hypothesized that targeting of ERp57 might be a potential treatment in cancerous and non-cancerous diseases.
Keywords
Cancer; ERp57; dysregulation; prognostic; diagnostic; target therapy
Cite This Article
Rahbar, F., Fagheh, A. F., Khosravi, A., Shariatzadeh, S., Akhavan-Sigari, R. (2021). A Review of the Role of ERp57 in Cancerous and Non-Cancerous Cell Physiology and its Potential as a Therapeutic Target. Molecular & Cellular Biomechanics, 18(4), 187–199.
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.